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Abstract
Background: Travelers to countries with high tuberculosis incidence can acquire infection during
travel. We sought to compare four screening interventions for travelers from low-incidence
countries, who visit countries with varying tuberculosis incidence.
Methods: Decision analysis model: We considered hypothetical cohorts of 1,000 travelers, 21
years old, visiting Mexico, the Dominican Republic, or Haiti for three months. Travelers departed
from and returned to the United States or Canada; they were born in the United States, Canada,
or the destination countries. The time horizon was 20 years, with 3% annual discounting of future
costs and outcomes. The analysis was conducted from the health care system perspective.
Screening involved tuberculin skin testing (post-travel in three strategies, with baseline pre-travel
tests in two), or chest radiography post-travel (one strategy). Returning travelers with tuberculin
conversion (one strategy) or other evidence of latent tuberculosis (three strategies) were offered
treatment. The main outcome was cost (in 2005 US dollars) per tuberculosis case prevented.
Results: For all travelers, a single post-trip tuberculin test was most cost-effective. The associated
cost estimate per case prevented ranged from $21,406 for Haitian-born travelers to Haiti, to
$161,196 for US-born travelers to Mexico. In all sensitivity analyses, the single post-trip tuberculin
test remained most cost-effective. For US-born travelers to Haiti, this strategy was associated with
cost savings for trips over 22 months. Screening was more cost-effective with increasing trip
duration and infection risk, and less so with poorer treatment adherence.
Conclusion:  A single post-trip tuberculin skin test was the most cost-effective strategy
considered, for travelers from the United States or Canada. The analysis did not evaluate the use
of interferon-gamma release assays, which would be most relevant for travelers who received BCG
vaccination after infancy, as in many European countries. Screening decisions should reflect
duration of travel, tuberculosis incidence, and commitment to treat latent infection.
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Background
In the United States, Canada, and other high-income
countries, the proportion of tuberculosis (TB) cases
among foreign-born individuals continues to increase
[1,2]. The foreign-born have markedly higher TB inci-
dence than persons born in low-incidence countries; the
discrepancy is most evident in the first years after arrival,
but persists for 20 years or longer [3]. This phenomenon
highlights the impact of migration from higher- to low-
incidence settings.
Travel to high-incidence settings is associated with
increased incidence of TB disease and latent infection.
Tuberculosis cases among established South Asian immi-
grants in London reflected return visits to their countries
of origin [4]. Visits to parents' countries of origin were a
consistent risk factor for latent TB infection among US-
born children of immigrants [5,6]. Among 656 Dutch-
born travelers to destinations with high TB incidence, the
estimated incidence of latent TB infection was 4.2 per 100
person-years [7], a figure which equals or exceeds the
annual risk of infection in the highest-incidence coun-
tries. Incidence was even higher for travelers engaged in
health care work [7].
The acquisition of tuberculosis infection during travel is
of particular concern, because of the high risk of active dis-
ease following new infection. The U.S. Centers for Disease
Control and Prevention recommend that travelers "who
anticipate possible prolonged exposure to tuberculosis"
should undergo tuberculin tests before and after travel,
while those "who anticipate repeated travel with possible
prolonged exposure or an extended stay over a period of
years in an endemic country" should undergo baseline
two-step tuberculin testing, with subsequent annual tests
if negative at baseline [8]. The Public Health Agency of
Canada recommends pre-trip (two-step) and post-trip
tuberculin tests for travelers who visit high-incidence
countries for three months or longer, and for travelers
engaged in any health care work in such countries [9].
To date, recommendations for traveler screening have
been based on expert opinion. Using a decision analysis
model, we conducted a cost-effectiveness analysis to eval-
uate four potential TB screening interventions for travelers
to higher-incidence countries.
Methods
Screening strategies
We considered three screening strategies based on tuber-
culin skin testing, and one based on chest radiography
(Table 1). Any positive tuberculin test was followed by
clinical evaluation and chest radiography to identify or
exclude active disease, with three mycobacterial cultures
of spontaneous or induced sputum when indicated.
Travelers diagnosed with active TB received standard drug
treatment. Depending on the strategy, some or all travel-
ers diagnosed with latent TB were prescribed a nine-
month course of isoniazid (Table 1).
Table 1: Summary of screening strategies
Strategy Pre-travel tuberculin skin test results Interpretation of pre-
travel results
Intervention
Test 1 Test 2
Pre-trip two step tuberculin 
test Treat converters
≥ 10 mm N/A Baseline latent 
tuberculosis infection 
(LTBI)
No intervention. Passive diagnosis of TB 
disease pursued if symptomatic post-travel.
<10 mm ≥ 10 mm Booster effect; no 
baseline LTBI
No intervention. Passive diagnosis of TB 
disease pursued if symptomatic post-travel.
<10 mm <10 mm No LTBI Post-trip tuberculin test. Converters 
prescribed isoniazid.
Pre-trip two step tuberculin 
test Treat reactors and 
converters
≥ 10 mm N/A Baseline LTBI Prescribe isoniazid.
<10 mm ≥ 10 mm Booster effect No intervention. Passive diagnosis of TB 
disease pursued if symptomatic post-travel
<10 mm <10 mm No LTBI Post-trip tuberculin test. Converters 
prescribed isoniazid
Post-trip tuberculin test None None One post-trip tuberculin skin test. All reactors 
(≥ 10 mm) prescribed isoniazid.
Post-trip chest x-ray None None Chest x-ray post-trip. Persons with 
radiographic abnormalities compatible with 
TB, negative workup for active TB, and TST ≥ 
5 mm prescribed isoniazid.
No screening No intervention before or after trip. Passive diagnosis of TB disease pursued if symptomatic post-travel.BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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For comparison, we included a strategy of no screening–
returning travelers presented to health facilities if they
developed TB symptoms.
The decision analysis model
We developed a decision analysis model, using DATA ver-
sion 4.0 for Health Care (TreeAge, Williamstown, MA).
The model incorporated multiple Markov processes,
including the following health states: uninfected, latent
TB infection, active TB disease, previous active disease
(recovered), and dead. Transitions reflected risks of
acquiring infection; risks of progression to active disease
depending on time since infection, and on treatment for
latent infection; cure rates with treatment of latent and
active TB; and risk of mortality from TB or other causes.
Figure 1 provides an overview. Further details are availa-
ble elsewhere [10].
We simulated tuberculosis-related events over 20 years,
beginning at departure, among 1000 travelers from the
United States or Canada who visited Mexico, the Domin-
ican Republic, or Haiti. We considered separately 1) trave-
lers born in the United States or Canada; and 2) travelers
residing in the United States or Canada, but born in Mex-
ico, the Dominican Republic, or Haiti, who made return
visits to their countries of birth. We considered these
Schematic view of decision trees Figure 1
Schematic view of decision trees. The top portion of the figure summarizes the sequence of events leading to possible 
tuberculosis infection after travel, and the use of post-travel screening (by skin testing or chest radiography) to detect latent 
infection or active disease. If two-step tuberculin skin testing is undertaken before travel, then post-travel testing is limited to 
travelers with negative baseline results, while those with positive baseline results may be referred for isoniazid treatment, as 
described in the text and in Table 1. Persons who return from travel with latent infection enter the Markov process illustrated 
in the lower portion of the figure, although those who receive isoniazid may be cured of latent infection and face no future risk 
of reactivation.BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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countries because they are frequent travel destinations,
and frequent countries of origin for foreign-born persons
in the United States and Canada. They span a range of TB
incidence relevant to many potential destinations.
Main outcomes were active tuberculosis cases, and costs.
While deaths were initially modeled, TB-related deaths
were so rare that differences between strategies were virtu-
ally non-existent, so deaths were not further analyzed.
Expected TB cases and costs were discounted at an annual
rate of 3% [11]. The analysis was conducted from the
health care system perspective. Model assumptions are
summarized in Table 2.
Travelers
In the base case analysis, we assumed that travelers were
21 years old and HIV-seronegative, and that those born
abroad had moved to the United States or Canada at age
11. Trips lasted three months. During travel, visitors faced
the same risks of TB infection as the local population, with
the same probability of infection with a drug-resistant
strain–as highlighted in Table 2[7]. The estimated annual
risks of TB infection in Mexico, the Dominican Republic,
and Haiti were 0.3%, 0.8%, and 2.6% respectively, using
the reported incidence of smear-positive disease in those
countries in 2004 [12] and the Styblo formula [13].
For travelers born abroad, the likelihood of latent TB
infection before travel reflected the annual risk in the
country of origin and the age (11 years) at which they
were assumed to have emigrated. Background mortality
rates were based on US and Canadian life tables [14,15].
All travelers were assumed to be HIV-seronegative, reflect-
ing the low prevalence of HIV infection in the US and
Canadian general population, and screening practices for
HIV among prospective immigrants to the US and Can-
ada. Clinical considerations would be very different for
HIV-infected travelers, who should undergo baseline TB
screening at the time of HIV diagnosis.
BCG vaccination
We considered that travelers born in Canada or the US
had not received the Bacille Calmette-Guérin (BCG) vac-
cine. Travelers born in Mexico, the Dominican Republic,
or Haiti were assumed to have received BCG vaccination
during infancy only, with probabilities equal to reported
coverage rates in those countries for the year 1984 (47%,
43%, and 71% respectively) [16]. BCG vaccination during
infancy did not provide any protection with respect to
active TB after travel, and we assumed it did not lead to
false-positive first-step tests [17,18]. However, we
assumed a 25% probability of boosting on the second-
step test among persons who had been BCG vaccinated
[17,18].
Secondary transmission
In addition to active TB cases among travelers themselves,
the analysis also incorporated latent infection and active
disease among their contacts. Our estimates reflected the
mathematical model of TB transmission developed by
Salpeter and Salpeter [19], the relative contagiousness of
smear-positive and smear-negative source patients with
pulmonary disease [20], and the proportion of smear-pos-
itive disease among persons diagnosed passively vs.
actively [21]. On these grounds, we estimated that persons
with active TB diagnosed passively on the basis of symp-
toms infected 3.5 contacts each, with 0.7 cases of second-
ary active disease, while persons with active TB diagnosed
by screening infected 1.5 contacts each, with 0.3 cases of
secondary active disease [22].
Loss to follow-up
Based on the Dutch study of travelers to high-incidence
countries, we assumed that 34% of travelers would be lost
to follow-up post-trip [7].
Costs
Component costs for US travelers were based on two US
surveys of TB-related health care costs [23,24]. Additional
US costs were obtained from the fee schedule published
by the US Centers for Medicare and Medicaid Services
[25]. Component costs for Canadian travelers were
derived from earlier program evaluations and cost-effec-
tiveness analyses from Montreal [22,26]. We assumed that
80% of persons with active TB diagnosed because of
symptoms would be hospitalized, while the correspond-
ing figure would be 50% for those diagnosed by screening
[21,26].
All costs were expressed in year 2005 US dollars (for US
travelers) or year 2005 Canadian dollars (for Canadians)
[27,28], $1 Canadian (2005) = $0.89 US (2005). Table 2
lists US cost estimates.
Sensitivity analyses
We ran one-way sensitivity analyses for all assumed
parameters. We repeated the analysis using alternative
visit durations (6–24 months) and traveler ages, and with
exclusion of cases and costs related to secondary transmis-
sion. Two-way sensitivity analysis evaluated the simulta-
neous influence of visit duration and annual risk of
infection in the destination country.
Research ethics
As this study did not involve human subjects, approval
from the institutional ethics review board was not
required.BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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Table 2: Model assumptions
Base value Range Sources
Annual risk of progression from latent tuberculosis (LTBI) to TB disease
Among persons newly infected during travel
First two years after infection 0.025 0.02 – 0.05 [33]
Subsequently 0.001 0.001 – 0.002 [34]
Among persons with LTBI before travel, given
No underlying radiographic abnormalities [see below] 0.001 [34]
Underlying radiographic abnormalities [see below] 0.0066 [34]
Reduction in risk afforded by:
Full 9 months of isoniazid, given drug-sensitive latent infection 90% [35]
<6 months isoniazid 0% [36]
Previous LTBI, among persons who are reinfected during travel 79% [37]
Prevalence of isoniazid resistance
Mexico 0.072 0.072 – 0.12 [38, 39]
Dominican Republic 0.198 -- [40]
Haiti 0.159 -- [41]
Active TB
Proportion of travelers with active TB symptomatic upon return 0.27 0.11 – 0.44 [21, 26]
Probability of hospitalization given active TB diagnosed after symptoms 0.8 [42]
Probability of hospitalization given active TB diagnosed through screening 0.5 [21, 22]
Probability of completing full anti-TB therapy 1.0 assumed
Risk of major side effect with full anti-TB therapy 0.051 0.01 – 0.1 [43]
Probability of death, given major treatment side effect 0.015 0.001 – 0.032 [43–45]
Treatment of latent TB infection
Probability of completing 9 months isoniazid 0.647 0.62 – 1 [10, 46]
Probability of major side effect with isoniazid 0.003 [43–45]
Probability of death, given major treatment side effect 0.015 0.001 – 0.032 [43–45]
Tuberculin skin testing
Probability of boosting, given previous BCG vaccination 0.25 [17]
Specificity for LTBI 0.875 - [17]
Sensitivity for LTBI 0.99 - [47, 48]
Sensitivity for active TB 0.88 - [48]
Probability of loss to follow-up between pre- and post- travel evaluations, for repeat testing 
strategies
0.34 [7]
Probability of abnormal chest X-ray upon return from travel
With preexisting LTBI 0.11 0.07 – 0.15 [33, 34, 49, 50]
With LTBI newly acquired during travel 0 assumed
With active TB 0.95 0.9 – 1 [51, 52]
Sputum cultures (3) for M. Tuberculosis
Specificity 0.99 [51]
Sensitivity 0.9 [53]
Costs for TB screening and care in the US (expressed in 2005 US dollars)
Initial clinic visit $68 [54, 25]
Tuberculin skin test $12 [42, 23]
Follow-up clinic visit after tuberculin test $36 [42]
Chest radiograph with reading $36 [42]
Isoniazid, 9 months supply $25 [54]
7 outpatient clinic visits during isoniazid treatment $385 [54]
Major adverse reaction to isoniazid $9,834 [54]
3 sputa for AFB smear and culture, after abnormal CXR $126 [55, 56]
Inpatient treatment of active TB disease $9,061 [57]
Outpatient treatment of active TB disease $2,600 [42]
Contact investigation and management, per active TB case (identified via screening) $4,483 [42, 24]BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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Results
Base case analysis
For every 1,000 US-born travelers who visited Mexico for
three months, the expected number of TB cases was 1.0
and the expected cost $7,428 over the 20-year simulation,
in the absence of any intervention (Table 3). Of the inter-
ventions considered, the single post-trip tuberculin skin
test was both the cheapest ($47,082 per 1,000 travelers)
and the most effective (0.2 cases prevented per 1,000
travelers) in this traveler group, but this intervention cost
an estimated $161,196 per case prevented, relative to no
intervention. For US-born travelers to the Dominican
Republic or Haiti, the same strategy was again cheapest
and most effective, but with an estimated cost of
$102,745 or $36,931 per case prevented, respectively. For
travelers born in the destination countries, the single post-
trip tuberculin test was also the preferred strategy (Table
3).
Costs were different for travelers departing from Canada,
but outcomes were similar. Hence as for US travelers, the
single post-trip tuberculin test prevented the most active
TB cases. This strategy was also cheaper than the other
interventions. However, the incremental cost per case pre-
vented was consistently higher than for US travelers–pri-
marily reflecting lower costs for TB-related hospitalization
in the Canada. For instance, among Canadian-born trave-
lers visiting Haiti for 3 months, it was $44,389 Canadian
($39,506 US) per TB case prevented.
Sensitivity Analyses
Regardless of trip duration, the single post-trip tuberculin
test was preferred, as it was consistently the cheapest inter-
vention per case prevented. All interventions became
more cost-effective with increasing length of stay abroad.
For example, among US-born travelers to Haiti, with a 24-
month trip, screening became cost saving (Table 4). In
fact, the single post-trip tuberculin testing strategy was
predicted to result in cost savings for US-born travelers
staying in Haiti for 21.8 months or longer. For Haitian-
born travelers from the US returning to Haiti, and for
travelers to Mexico or the Dominican Republic, this strat-
egy was not expected to produce cost savings for stays up
to 24 months.
For Canadian-born travelers to Haiti, the post-trip tuber-
culin test became cost saving for trips over 17.4 months.
For all other travelers departing from Canada, no cost sav-
ings were predicted for trips up to 24 months.
As the risk of infection increased, all interventions became
more cost-effective; the single post-trip tuberculin test
remained the preferred strategy. The results of a formal
two-way sensitivity analysis evaluating the impact of
infection risk and visit duration on the post-trip screening
strategy are shown in Figure 2. The post-trip TST strategy
became cost-saving for longer visit durations, very high
infection risks, or both.
With older traveler age, the cost per case prevented
increased. This reflected the increased background mortal-
ity rate, and the higher risk of side effects with treatment
of latent infection. However, this effect was relatively
modest (Table 4).
We repeated the analysis with the same base case parame-
ters, except that secondary transmission was ignored. This
led to fewer expected cases (particularly in the absence of
any intervention) but screening costs were unchanged.
Hence the costs of all interventions increased relative to
the number of cases prevented. For example, the cost per
case prevented among US-born travelers visiting Haiti for
3 months increased from $36,931 to $41,598.
Any refusal to undergo screening would reduce the public
health impact of all interventions. Failure to return for fol-
low-up after skin testing would reduce the cost-effective-
ness of each intervention. This was particularly true for the
two strategies which involved pre-travel tuberculin tests,
so that these strategies were even less attractive when we
increased the probability of loss to follow-up above the
base case value of 34%.
Regardless of the assumed completion rate for isoniazid
treatment, the single post-trip tuberculin test remained
the preferred intervention. However, the completion rate
substantially affected the number of cases prevented by
each intervention, and thus the cost per case prevented
(Table 4).
Discussion
For three-month trips to most destinations, tuberculosis
screening by any method is expensive, and yields a limited
absolute reduction in subsequent TB incidence. For trips
of six or more months to high-incidence destinations, a
single post-trip tuberculin skin test is reasonably cost-
effective, and may be cost-saving under some conditions.
For such trips, screening is particularly relevant for health
care workers, and for travelers visiting friends and rela-
tives. On the other hand, screening would be even less
cost-effective for typical trips of 1–2 weeks, and for visits
to tourist resorts.
The single post-trip tuberculin test is clearly preferable to
repeated testing pre and post-travel, and to chest radiogra-
phy, across a wide variety of settings and assumptions.
The single test is more effective, in that there may be fewer
opportunities for losses to follow-up than with the
repeated pre-travel screens (an important assumption),BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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Table 3: Base case analysis: Cost-effectiveness of screening 21 year-old travelers for 3-month trips
Traveler's destination Traveler group: 
Annual risk of infection Screening 
strategy from least to most expensive
Expected costs per 
1,000 (2005 USD)
Expected cases per 
1,000
Incremental cost per 
1,000†
Incremental cases 
prevented per 1,000†
Incremental cost per 
case prevented†
Travelers to Mexico
US-born: Annual infection risk 0.3%
No screening $7,428 1.0 - - -
Post-trip TST $47,082 0.8 $39,654 0.2 $161,196
Post-trip chest x-ray $58,972 0.9 $11,890 (0.1) Dominated
Pre & post trip TST; treatment 
for reactors
$68,644 0.8 $9,672 0.1 Dominated
Pre & post trip TST; treatment 
for converters only
$68,741 0.9 $97 (0.1) Dominated
Mexican-born: Annual infection risk 
0.3%
No screening $9,855 1.3 - - -
Post-trip TST $57,666 1.0 $47,811 0.3 $143,578
Post-trip chest x-ray $61,087 1.1 $3,421 (0.1) Dominated
Pre & post trip TST; treatment 
for converters only
$71,335 1.2 $10,248 (0.1) Dominated
Pre & post trip TST; treatment 
for reactors
$74,372 1.1 $3,037 0.1 Dominated
Travelers to Dominican 
Republic
US-born: Annual infection risk 0.8%
No screening $13,226 1.7 - - -
Post-trip TST $51,961 1.3 $38,735 0.4 $102,745
Post-trip chest x-ray $64,678 1.6 $12,718 (0.3) Dominated
Pre & post trip TST; treatment 
for reactors
$73,792 1.4 $9,114 0.2 Dominated
Pre & post trip TST; treatment 
for converters only
$73,889 1.5 $97 (0.1) Dominated
Dominican-born: Annual infection 
risk 0.8%
No screening $25,423 3.3 - - -
Post-trip TST $73,523 2.6 $48,100 0.7 $65,264
Post-trip chest x-ray $75,711 2.9 $2,188 (0.3) Dominated
Pre & post trip TST; treatment 
for reactors
$86,604 2.8 $10,893 0.1 Dominated
Pre & post trip TST; treatment 
for converters only
$89,568 3.2 $2,964 (0.4) Dominated
Travelers to Haiti
US-born: Annual infection risk 2.6%
No screening $34,041 4.4 - - -
Post-trip TST $68,756 3.5 $34,715 0.9 $36,931
Post-trip chest x-ray $85,163 4.3 $16,407 (0.8) Dominated
Pre & post trip TST; treatment 
for reactors
$91,797 3.8 $6,634 0.5 Dominated
Pre & post trip TST; treatment 
for converters only
$91,893 3.9 $96 (0.1) Dominated
Haitian-born: Annual infection risk 
2.6%
No screening $73,594 9.6 - - -
Post-trip chest x-ray $119,983 8.5 $46,389 1.1 $40,585*
Post-trip TST $121,073 7.4 $1,090 1.1 $1,014
Pre & post trip TST; treatment 
for reactors
$133,556 8.1 $12,484 (0.7) Dominated
Pre & post trip TST; treatment 
for converters only
$135,395 9.2 $1,839 (1.1) Dominated
†For each type of traveler, strategies are listed by increasing cost. In the three rightmost columns, the calculation of incremental values (e.g., 
incremental cost per 1,000) is based on the comparison between each strategy and its next least costly alternative (e.g., a row might show the 
difference in cost between the second least costly strategy and the least costly strategy; the next row below would then show the cost difference 
between the third and second least costly strategies; and so on). Values in parentheses indicate an increase in expected cases, instead of cases 
prevented. "Dominated" means that another strategy is available that is both less costly and effective in preventing more TB cases.
*Dominated by extended dominance. While post-trip chest X-ray is the least costly option, another choice is available which is more attractive on an 
incremental cost per case prevented basis. The incremental cost per TB case prevented of post-trip TST, compared to no screening, is $21,406.BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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Table 4: Sensitivity analysis: Incremental cost per tuberculosis case prevented by post-trip tuberculin testing (versus no screening)
All costs in 2005 US dollars
Mexico Dominican Republic Haiti
Annual risk of infection 0.3% Annual risk of infection 0.8% Annual risk of infection 2.6%
US-born Mexican-born US-born Dominican-born US-born Haitian-born
Base case $161,196 $143,578 $102,745 $65,264 $36,931 $21,406
Increase traveler age from 21 years† to 35 years $163,779 $148,268 $103,993 $67,644 $37,482 $22,651
to 55 years $178,237 $164,591 $113,168 $76,263 $40,989 $26,537
Increase trip duration from 3 
months†
to 6 months $111,832 $60,889 $16,787 $108,476 $48,731 $15,261
to 12 months $67,592 $71,720 $31,427 $31,217 $5,426 $8,554
to 24 months $35,872 $41,050 $13,622 $16,510 Cost saving $2,740
Change isoniazid completion rate 
from 65%†
to 50% $208,386 $185,056 $132,752 $84,964 $48,813 $29,113
to 100% $103,191 $93,192 $65,368 $41,179 $22,017 $12,007
†All other parameters held constant at base case value
Two-way sensitivity analysis examining the impact of travel duration and annual risk of infection on potential cost savings with  the post-trip tuberculin testing strategy, for US-born travelers Figure 2
Two-way sensitivity analysis examining the impact of travel duration and annual risk of infection on potential 
cost savings with the post-trip tuberculin testing strategy, for US-born travelers. During longer trips and/or high 
annual infection risks, this approach becomes cost-saving, relative to no screening. The two-way sensitivity analysis assumes a 
7.2% prevalence of isoniazid resistance, as in Mexico. Hence the threshold trip duration for cost savings among travelers facing 
infection risks as in the Dominican Republic and Haiti is shorter than in the base case scenario. The base case scenario used the 
higher prevalence of isoniazid resistance which has been documented in those countries (19.8% and 15.9%).
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and many more cases of new infection diagnosed than
with chest radiography.
A post-travel tuberculin test alone cannot distinguish
remote from recently acquired infection. However, for
travelers born in the United States or Canada who visit
high-incidence countries, positive post-travel tests will
often reflect infection acquired during travel. For travelers
born in high-incidence countries, positive post-travel tests
may reflect longstanding infection, but treatment will still
be beneficial–particularly for younger travelers–and per-
sons with newly acquired infection will still be referred for
treatment. We used a 10 mm threshold, as would ordinar-
ily be used for HIV-seronegative persons moving to the
United States or Canada from abroad. We did not con-
sider the 5 mm cutoff used for contact investigation, for
persons with HIV infection, or those with other major risk
factors for reactivation, as such individuals represent a
small minority of travelers and were not the focus of this
analysis.
The decision analysis allowed us to explicitly model the
different elements of each intervention, and key parame-
ters influencing costs and clinical impact. Predicted costs
and numbers of tuberculosis cases varied considerably
under different scenarios, notably infection risk and travel
duration. However, the single post-trip tuberculin test
remained the preferred intervention across all scenarios
considered.
We limited the analysis to the perspective of the health
care system, since we did not have reliable estimates for
lost earnings and out-of-pocket costs associated with
screening. Adoption of this perspective meant that lost
earnings and patient costs related to active TB were
ignored, but it also meant that we did not consider time
lost from work to undergo screening. Given the small
number of active cases prevented, relative to the number
of travelers screened, it is possible that incorporation of
time lost from work would actually increase costs per case
prevented. This is particularly likely for the two strategies
which involved two-step skin tests before departure.
Another limitation of this analysis was the use of tubercu-
losis cases as the primary outcome measure. The ideal is to
express effectiveness in terms of quality-adjusted survival,
but TB-related mortality is extremely rare among HIV-neg-
ative persons treated in the United States and Canada,
while reliable data reporting quality adjustment for TB-
related morbidity are scarce [29].
Our analysis was limited to travelers leaving from and
returning to the United States or Canada, and used cost
estimates from those countries. The expected costs of the
four screening strategies for travelers from other low-inci-
dence countries would vary according to the costs of the
individual screening components, of TB drugs, and of TB
care in those countries. However, if the relative costs of
screening versus TB care are similar to those in the US and
Canada, then the single post-trip test would likely remain
the preferred option.
For three month visits to Mexico and the Dominican
Republic, the estimated cost per case prevented by the
post-trip tuberculin testing strategy compared poorly to
established interventions, such as chest radiographic
screening of immigrant applicants entering Canada [26]
where the estimated cost was $48,473 Canadian ($43,141
US). For three-month visits to Haiti, the cost per case pre-
vented was more comparable, though still much greater
than the estimated $561 US per case prevented through
screening high-risk kindergarten pupils in the US [24].
A potential limitation of this analysis was the estimate of
annual risk of infection, obtained by applying the Styblo
formula to reported incidence of smear-positive disease in
the three countries we considered. This formula was
derived before the advent of the HIV epidemic and may
not accurately estimate the precise infection risk in each
country. However, we considered a wide range of infec-
tion risk, with consistent results in terms of the preferred
strategy.
In clinical practice, travelers might be more often lost to
follow-up than the 34% lost to follow-up in the Dutch
cohort study [7]. In that setting, travelers volunteered to
participate in a research study, underwent two-step testing
before departure, and were actively followed up after their
return. Loss to follow-up after travel substantially dimin-
ishes the cost-effectiveness of strategies with baseline test-
ing pre-travel, since anyone lost to follow-up incurs
screening costs without benefit. With the single tuberculin
test, travelers who elect not to be tested after their return
neither incur screening costs nor derive benefit. Hence the
absolute public health impact is reduced, but not the cost-
effectiveness.
One alternative intervention that would reduce the incon-
venience of repeated testing and reading is the use of inter-
feron-gamma release assays. These also potentially offer
enhanced specificity for the diagnosis of latent TB in indi-
viduals who received BCG vaccination after infancy
[30,31]. Because of the unit costs of these tests, their use
could be considerably more expensive than that of tuber-
culin testing for most travelers. However, they could
reduce the frequency of unnecessary treatment among
travelers who were BCG-vaccinated after infancy. In this
analysis we focused on individuals born in the United
States or Canada–who are not ordinarily vaccinated–and
on foreign-born persons vaccinated only at birth.BMC Public Health 2008, 8:201 http://www.biomedcentral.com/1471-2458/8/201
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Use of an interferon-gamma release assay would be most
relevant, and potentially cost-effective, for travelers born
in countries where the BCG vaccination is administered
after infancy, as in many European countries. A single
post-trip test with one of the newer-generation interferon-
gamma release assays might be considered as an alterna-
tive in such travelers, to avoid potential confounding by
BCG vaccination after infancy. However, a formal cost-
effectiveness evaluation of this option was beyond the
scope of the current analysis. Interested readers are
referred to a recently published cost-effectiveness analysis
which compared interferon-gamma release assays with
tuberculin tests and chest X-rays for TB screening, among
close contacts and immigrants. The analysis highlighted
the potential utility of interferon-gamma release assays as
confirmatory tests for latent infection, after positive tuber-
culin tests in persons from countries where BCG is repeat-
edly administered [32].
The decision to screen for latent TB among travelers must
take into account the duration of the trip, the risk of infec-
tion in the destination country, and the likelihood of
exposure (e.g. health care workers). For healthy travelers
visiting destinations with high TB incidence, it may be rea-
sonable to consider screening for trips lasting 6 or more
months. For individual travelers, the decision must also
account for factors that increase the risk of subsequent
active TB (e.g. immune suppression, diabetes) as well as
factors that increase the risk of treatment toxicity. If
screening is undertaken, travelers should plan a single
tuberculin test after returning home.
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